Illumina price target lowered to $90 from $110 at BofA
BofA lowered the firm’s price target on Illumina (ILMN) to $90 from $110 and keeps an Underperform rating on the shares. Shares have fallen 25% ...
Global Market for Rare Disease Diagnostics to Grow at 9.9% CAGR
According to the latest study from BCC Research, "Rare Disease Diagnostics: Technologies and Global Markets" is projected to ...
Illumina's SWOT analysis: stock outlook amid sequencing market shifts
Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
ThePrint5d
How Chinese biotech firm BGI grew to rival US giant Illumina & enter US-China tariff war
China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...